Literature DB >> 26377173

Deterioration of renal function at stent implantation can predict long-term outcome after stent thrombosis.

Vojko Kanic1, Meta Penko2, Franjo Husam Naji2, Robert Ekart3,4, Zlatka Kanic5, Dejan Dinevski4, Radovan Hojs4,6.   

Abstract

OBJECTIVES: The aim of the study was to examine the possible influence of minor deterioration of the renal function after stent implantation not fulfilling the criteria for acute kidney injury on long-term outcomes after stent thrombosis (ST).
BACKGROUND: Decreased renal function (DRF) is associated with an increased risk for worse outcome after percutaneous coronary intervention. There is no data if the deterioration of renal function after stent implantation influences the prognosis after ST. If so patients with a higher risk for worse outcome after ST could be identified already at the time of stent implantation.
METHODS: Data from 4824 consecutive patients treated with percutaneous coronary intervention in our center was recorded from March 2004 to April 2010. We excluded patients with acute kidney injury at stent implantation and 86 of them with ST without acute kidney injury at stent implantation were involved in the study. They were prospectively followed until December 2012 for 50.2 ± 28.1 months. Only patients with definite ST were included in the study. The Academic Research Consortium definition of ST was used. Data on death, myocardial infarction, and repeated percutaneous or operative revascularization after ST were ascertained from the hospital database, by phone or with clinical examinations. The outcomes after definite ST were compared in patients with and without deterioration of renal function after stent implantation (DRFafterSI).
RESULTS: During the observational period patients with DRFafterSI had a higher mortality rate after ST than patients without DRFafterSI (35.1 vs. 10.3 %; p <0.019). The incidence of major adverse cardiac events (major adverse coronary event (MACE)-death, myocardial infarction, repeated revascularization) rate after ST was similar in both groups (66.1 % with DRFafterSI vs. 55.2 % without DRFafterSI). The prevalence of myocardial infarction was also similar in both groups (31.6 vs. 34.5 %) as was the revascularizations rate (43.9 vs. 48.3 %). Death was predicted by DRFafterSI (adjusted hazard ratio (HR) 3.96; 95 % confidence interval (CI) 1.11 to 14.10; p <0.034) and age > 75 years (adjusted HR 2.85: 95 % CI 1.12-7.30; p = 0.029). We could not find any predictor for MACE.
CONCLUSIONS: Even more subtle DRFafterSI (not fulfilling the criteria for acute kidney injury) at stent implantation were associated with higher long-term mortality after ST. Especially at risk were patients older than 75 years at stent implantation. DRFafterSI and age more than 75 years pointed out the group of patients with a high risk for death after ST already at the time of stent implantation. The best treatment option for preventing ST in these patients is still to be determined. Until then, we must pay a special attention to proper patients' preparation and hydration to avoid DRFafterSI.

Entities:  

Keywords:  Stent thrombosis; mortality; myocardial infarction; renal function deterioration; revascularization

Mesh:

Year:  2015        PMID: 26377173     DOI: 10.1007/s00508-015-0844-1

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  37 in total

1.  Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials.

Authors:  D E Cutlip; D S Baim; K K Ho; J J Popma; A J Lansky; D J Cohen; J P Carrozza; M S Chauhan; O Rodriguez; R E Kuntz
Journal:  Circulation       Date:  2001-04-17       Impact factor: 29.690

2.  Clinical presentation, management, and outcomes of angiographically documented early, late, and very late stent thrombosis.

Authors:  Ehrin J Armstrong; Dmitriy N Feldman; Tracy Y Wang; Lisa A Kaltenbach; Khung-Keong Yeo; S Chiu Wong; John Spertus; Richard E Shaw; Robert M Minutello; Issam Moussa; Kalon K L Ho; Jason H Rogers; Kendrick A Shunk
Journal:  JACC Cardiovasc Interv       Date:  2012-02       Impact factor: 11.195

3.  Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up.

Authors:  Duk-Woo Park; Seong-Wook Park; Kyoung-Ha Park; Bong-Ki Lee; Young-Hak Kim; Cheol Whan Lee; Myeong-Ki Hong; Jae-Joong Kim; Seung-Jung Park
Journal:  Am J Cardiol       Date:  2006-06-12       Impact factor: 2.778

4.  Stent thrombosis following bare-metal stent implantation: success of emergency percutaneous coronary intervention and predictors of adverse outcome.

Authors:  Peter Wenaweser; Christoph Rey; Franz R Eberli; Mario Togni; David Tüller; Stefan Locher; Andrea Remondino; Christian Seiler; Otto M Hess; Bernhard Meier; Stephan Windecker
Journal:  Eur Heart J       Date:  2005-02-23       Impact factor: 29.983

5.  Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials.

Authors:  Anthony A Bavry; Dharam J Kumbhani; Thomas J Helton; Przemyslaw P Borek; Girish R Mood; Deepak L Bhatt
Journal:  Am J Med       Date:  2006-12       Impact factor: 4.965

6.  Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals.

Authors:  Linda F Fried; Michael G Shlipak; Casey Crump; Anthony J Bleyer; John S Gottdiener; Richard A Kronmal; Lewis H Kuller; Anne B Newman
Journal:  J Am Coll Cardiol       Date:  2003-04-16       Impact factor: 24.094

7.  Are patients with renal failure good candidates for percutaneous coronary revascularization in the new device era?

Authors:  M H Rubenstein; L C Harrell; B V Sheynberg; H Schunkert; H Bazari; I F Palacios
Journal:  Circulation       Date:  2000-12-12       Impact factor: 29.690

8.  Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial.

Authors:  Roxana Mehran; Alexandra J Lansky; Bernhard Witzenbichler; Giulio Guagliumi; Jan Z Peruga; Bruce R Brodie; Dariusz Dudek; Ran Kornowski; Franz Hartmann; Bernard J Gersh; Stuart J Pocock; S Chiu Wong; Eugenia Nikolsky; Louise Gambone; Lynn Vandertie; Helen Parise; George D Dangas; Gregg W Stone
Journal:  Lancet       Date:  2009-08-28       Impact factor: 79.321

9.  Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial.

Authors:  Stephen D Wiviott; Eugene Braunwald; Carolyn H McCabe; Ivan Horvath; Matyas Keltai; Jean-Paul R Herrman; Frans Van de Werf; William E Downey; Benjamin M Scirica; Sabina A Murphy; Elliott M Antman
Journal:  Lancet       Date:  2008-04-02       Impact factor: 79.321

10.  Proposed declassification of disease categories related to sexual orientation in the International Statistical Classification of Diseases and Related Health Problems (ICD-11).

Authors:  Susan D Cochran; Jack Drescher; Eszter Kismödi; Alain Giami; Claudia García-Moreno; Elham Atalla; Adele Marais; Elisabeth Meloni Vieira; Geoffrey M Reed
Journal:  Bull World Health Organ       Date:  2014-06-17       Impact factor: 9.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.